UNBX — Unity Biotechnology Share News
0.000.00%
Last trade - 00:00Brief: Unity Biotech Doses First Patient In Envision, Phase 2 Study Of UBX1325
Brief: UNITY Biotechnology Completes Enrollment in Phase 2 Study of UBX1325 in Diabetic Macular Edema
Piper Sandler cuts PT on cloud software stocks with high international exposure
Brief: Unity Biotechnology Files For Mixed Shelf Of Up To $125 Million
Brief: Unity Biotechnology Posts Qtrly Loss Per Share 18 Cents
U.S. STOCKS ON THE MOVE-Oil stocks, AMD, Walmart, Lockheed Martin, Moderna
UNITY Biotech rises on additional data from eye drug trial
Brief: Unity Biotechnology Announces Additional Data From Phase 1 Study Of Ubx1325 In Advanced Vascular Eye Disease
Brief: Unity Biotechnology Announces Restructuring To Advance Corporate Strategy And Focus On Key Ophthalmology Programs
Brief: Unity Biotechnology Provides Program Updates And Anticipated Milestones For 2022
Brief: Unity Biotechnology Announces Exclusive License Agreement With Jocasta Neuroscience To Continue Development Of Α-Klotho Program
U.S. STOCKS ON THE MOVE-PubMatic, Unity Biotech, Seres Therapeutics
U.S. STOCKS ON THE MOVE-RingCentral, Open Lending, Wendy's
Unity Biotechnology Inc Reports Results For The Quarter Ended In September: Earnings Summary
Brief: Unity Biotechnology Reports Qtrly Net Loss Per Share Of $0.30
U.S. STOCKS ON THE MOVE-Tesla, Fiverr, RingCentral
U.S. STOCKS ON THE MOVE-Poshmark, Open Lending, Unity Biotech
Unity Biotech extends gains as Mizuho upgrades on eye drug potential
Brief: Unity Biotechnology Announces Improvement In Visual Acuity Sustained Through 24 Weeks Following Single Dose Of UBX1325 In Phase 1 Study